# US 2017/0246251 A1 · Therapeutic il-13 polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0246251 A1
- Document ID: US20170246251A1
- Status: Published application
- Kind: A1
- Application number: 15/597,823
- Filed: 2017-05-17
- Published: 2017-08-31
- Earliest claimed: 2012-01-27
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Kenan Christopher Garcia; Ignacio Moraga Gonzalez
- Web page: https://patentgrep.com/patent/US20170246251A1

## CPC

- C07K 14/5437: {IL-13}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G09G 3/2003: {Display of colours (specific for liquid crystal displays G09G3/3607)}
- G09G 3/2074: {using sub-pixels}
- H04N 19/176: the region being a block, e.g. a macroblock
- H04N 19/182: the unit being a pixel
- A61K 38/2086: {IL-13 to IL-16}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G09G 2320/0247: Flicker reduction other than flicker reduction circuits used for single beam cathode-ray tubes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G09G: ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION (arrangements for transferring data between digital computers and displays G06F3/14; static indicating arrangements comprising an association of a number of separate sources or light control cells G09F9/00; static indicating arrangements comprising integral associations of a number of light sources H01J, H01K, H10H, H05B33/12; scanning, transmission or reproduction of documents or the like, e.g. facsimile transmission, details thereof H04N1/00)
- H04N: PICTORIAL COMMUNICATION, e.g. TELEVISION
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13Rα2, relative to the native human IL-13 protein; (b) altered affinity for IL-13Rα1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4Rα relative to the native human IL-13 protein.

## Claims

### Claim 1

A polypeptide comprising:
a modified interleukin 13 (IL-13) engineered to have increased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein; (b) and decreased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL 13 protein;
wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions L10, R86, D87, T88 and R108.

### Claim 2 (depends on 1)

The modified IL-13 polypeptide of claim 1, comprising a set of amino acid substitutions:
[L10H, R86T, D87G, T88R, R108K].

### Claim 3 (depends on 2)

The modified IL-13 polypeptide of claim 2, comprising an amino acid sequence set forth in SEQ ID NO:18.

### Claim 4 (depends on 1)

The polypeptide of claim 1, conjugated or fused to a therapeutic or labeling moiety.

### Claim 5 (depends on 4)

The polypeptide of claim 4, wherein the therapeutic moiety is a heterologous polypeptide fused to the modified IL-13 polypeptide.

### Claim 6 (depends on 5)

The polypeptide of claim 5, wherein the heterologous polypeptide is a cytotoxin.

### Claim 7 (depends on 5)

The polypeptide of claim 5, wherein the heterologous polypeptide comprises an IgG Fc region.

### Claim 8 (depends on 1)

The polypeptide of claim 1 in a pharmaceutical formulation.

### Claim 9

A modified IL-13 antagonist polypeptide engineered to have decreased affinity for interleukin 13 receptor α2 (IL-13Rα2), relative to native human IL 13 protein; (b) and increased affinity for interleukin 13 receptor α1 (IL-13Rα1) relative to native human IL 13 protein, wherein the modified IL-13 polypeptide comprises amino acid changes relative to wild type IL-13 at positions V18, D87, T88, L101, K104, and K105; and comprising amino acid substitutions E12A/G/S and R65D/E, wherein the polypeptide is conjugated or fused to a therapeutic or labeling moiety.

### Claim 10 (depends on 9)

The modified IL-13 polypeptide of claim 9, comprising a set of amino acid substitutions selected from
[L10V, V18I, D87S, T88S, L101F, K104R, K105T];
[V18I, R86T, D87G, T88S, L101Y, K104R, K105A]; and
[R11I, V18I, R86K, D87G, T88S, L101H, K104R, K105A, F107M].

### Claim 11 (depends on 9)

The polypeptide of claim 9, wherein the therapeutic moiety is a heterologous polypeptide fused to the modified IL-13 polypeptide.

### Claim 12 (depends on 11)

The polypeptide of claim 11, wherein the heterologous polypeptide is a cytotoxin.

### Claim 13 (depends on 11)

The polypeptide of claim 11, wherein the heterologous polypeptide comprises an IgG Fc region.

### Claim 14 (depends on 9)

The polypeptide of claim 9 in a pharmaceutical formulation.

### Claim 15 (depends on 1)

A nucleic acid encoding the polypeptide of claim 1.

### Claim 16 (depends on 15)

The nucleic acid of claim 15, further comprising a sequence encoding a heterologous polypeptide fused to the modified IL-13 coding sequence.

### Claim 17 (depends on 15)

The nucleic acid of claim 15, wherein the nucleic acid is present in a vector.

### Claim 18 (depends on 9)

A nucleic acid encoding the polypeptide of claim 9.

### Claim 19 (depends on 18)

The nucleic acid of claim 18, wherein the nucleic acid is present in a vector.
